ArticleThe American journal of pathology1995
c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.
Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 90 citations in OpenAlex.
- From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.Cancers · 2025Review
- The roles of FGFR3 and c-MYC in urothelial bladder cancer.Discover oncology · 2024Review
- Expression of proto-oncogene c-Myc in patients with urinary bladder transitional cell carcinoma.Current urology · 2021Article
- High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone.Journal of diabetes research · 2019Article
- Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.Oncotarget · 2018Article
- Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.European urology · 2017Review
- Rab23 is overexpressed in human bladder cancer and promotes cancer cell proliferation and invasion.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.Oncotarget · 2015Article
- c-MYC is a radiosensitive locus in human breast cells.Oncogene · 2015Article
- A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines.Canine genetics and epidemiology · 2015Article
- Therapeutic strategies to inhibit MYC.Cold Spring Harbor perspectives in medicine · 2014Review
- Mapping of the chromosomal amplification 1p21-22 in bladder cancer.BMC research notes · 2014Article
- Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.British journal of cancer · 2014Article
- Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.Journal of gastrointestinal cancer · 2011Review
- Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations.Carcinogenesis · 2011Article
- Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer.British journal of cancer · 2002Article
- Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.British journal of cancer · 2001Article
- Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization.The American journal of pathology · 1998Article
- Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer.The American journal of pathology · 1997Article
- c-myc in bladder cancer. Clinical findings and analysis of mechanism.Urological research · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Amplification and overexpression of c-myc have been suggested as prognostic markers in human cancer. To assess the role of c-myc gene copy number alterations in bladder cancer, 87 bladder tumors were examined for c-myc aberrations by fluorescence in situ hybridization. Dual labeling hybridization with a repetitive pericentromeric probe specific for chromosome 8 and a probe for the c-myc locus (at 8q24) was performed to analyze c-myc copy number in relation to chromosome 8 copy number on a cell by cell basis. A clear-cut c-myc amplification (up to 40 to 150 copies per cell) was found in 3 tumors. There was a low level c-myc copy number increase in 32 of the remaining 84 tumors. There was no association of low level c-myc copy number increase with c-myc protein overexpression. This suggests that a c-myc gene copy number gain as detected by fluorescence in situ hybridization does not necessarily reflect a disturbed c-myc gene function but may indicate a structural chromosome 8 abnormality including gain of distal 8q. The strong association of low level c-myc (8q) gains with tumor grade (P < 0.0001), stage (P < 0.0001), chromosome polysomy (P < 0.0001), p53 protein expression (P = 0.0019), p53 deletion (P = 0.0403), and tumor cell proliferation (Ki67 labeling index; P = 0.0021) is consistent with a role of chromosome 8 alterations in bladder cancer progression.
Indexed as
Identifiers
7747807PMC1869279W1554018027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.